Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20511262 | 0.98 | BPTF (0.51) | BPTFGRM1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL20140205 | 0.77 | GRM1 (0.47) | GRM1CHRNB4CHRNA3HTR7TMEM97 | |
| SCHEMBL30619380 | 0.77 | GRM1 (0.49) | GRM1HTR7TMEM97DRD4DRD2 | |
| SCHEMBL27488325 | 0.77 | GRM1 (0.49) | GRM1HTR7TMEM97DRD4DRD2 | |
| SCHEMBL20129652 | 0.77 | GRM1 (0.46) | GRM1HTR7TMEM97DRD4DRD2 | |
| SCHEMBL20139200 | 0.76 | GRM1 (0.43) | GRM1CHRNB2CHRNA4HTR7TMEM97 | |
| SCHEMBL20157461 | 0.76 | GHSR (0.44) | GRM1HTR7TMEM97DRD4GRM5 | |
| SCHEMBL18452919 | 0.75 | HRH3 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3DRD2 | |
| SCHEMBL14704616 | 0.75 | ADRB1 (0.56) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22720929 | 0.75 | BPTF (0.56) | BPTFCHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-11807642-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-07 | — | — | US | disclosed |
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-22 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | BPTF 3839/4885GRM1 227/4885CHRNA7 161/4885 |
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | HTR7, HTR6, HTR5A | BPTF 2548/4885GRM1 124/4885CHRNA7 64/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | BPTF 3853/4885GRM1 198/4885CHRNA7 148/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | BPTF 3853/4885GRM1 198/4885CHRNA7 148/4885 |
| US-11807642-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | BPTF 2548/4885GRM1 124/4885CHRNA7 64/4885 |
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | BPTF 2548/4885GRM1 124/4885CHRNA7 64/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | BPTF 3839/4885GRM1 227/4885CHRNA7 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.